The U.S. Food and Drug Administration granted orphan drug designation to Partner Therapeutics Inc.’s Leukine (sargramostim), a yeast-derived recombinant human granulocyte-macrophage colony stimulating factor, for the potential treatment of Stage IIb-IV melanoma.